Key Highlights
- Personalis expands AI-powered NeXT Personal® MRD platform to colorectal cancer, supported by interim data from the VICTORI study.
- Collaboration with Tempus extended through 2029, accelerating adoption through its network reaching over 50% of U.S. oncologists.
- AI-driven tumor-informed testing positions MRD as the next frontier in personalized oncology care and reimbursement pathways.
AI at the Core of Next-Gen Recurrence Monitoring
The expansion of Personalis’ NeXT Personal® MRD test into colorectal cancer marks a pivotal moment for AI-enabled diagnostics. The test, powered by proprietary algorithms that integrate tumor-normal genomic profiling, delivers ultra-sensitive detection of minimal residual disease. Interim results from the VICTORI study presented at AACR 2025 confirm the platform’s ability to identify early signs of colorectal cancer recurrence—before conventional imaging or symptoms emerge. This signals a paradigm shift in how AI can help clinicians stay ahead of cancer progression.
Tempus Partnership Unlocks Scalable AI Deployment
By extending its exclusive commercialization agreement with Tempus through 2029, Personalis ensures that its AI-powered MRD test reaches oncologists at scale. Tempus’ reach—over 50% of U.S. oncologists—and its own data infrastructure provide a powerful distribution and analytics engine. The collaboration now spans four major cancer indications: breast, lung, colorectal, and solid tumors under immunotherapy monitoring. With this reach, AI insights from NeXT Personal® can rapidly translate into real-world clinical decisions across cancer care.
Precision Insights Meet Real-World Oncology Workflows
The NeXT Personal® test is not just sensitive—it’s intelligent. Its AI-enhanced algorithms adjust to tumor evolution, delivering continuous, personalized insights that support treatment modifications and surveillance planning. In combination with Tempus’ clinical data integration capabilities, the MRD platform becomes a decision-support layer, not just a diagnostic. This is precision oncology as it was always envisioned: adaptive, real-time, and patient-specific.
Advancing the Case for AI-Driven Reimbursement Models
With colorectal cancer now in scope, Personalis strengthens its clinical evidence base to support payer adoption. The expanded collaboration allows for longitudinal data collection and validation across multiple tumor types—an essential step toward coverage. AI’s role is central: delivering reproducible, high-confidence signals that meet payer demands for clinical utility. Personalis’ CEO Chris Hall underscores that this isn’t just a technological evolution—it’s a mission to provide clarity and confidence to every cancer survivor facing uncertainty.
About Personalis
Personalis, Inc. (Nasdaq: PSNL) is a leader in advanced genomics and AI-driven precision oncology. The company is transforming cancer management through its NeXT Personal® platform, which enables ultra-sensitive detection of minimal residual disease (MRD) and cancer recurrence. By combining tumor-informed testing with proprietary bioinformatics, Personalis empowers clinicians with deeper genomic insights for personalized treatment and monitoring across multiple cancer types. Headquartered in Fremont, California, Personalis supports both clinical and biopharma partners in driving the next generation of oncology care.
About Tempus
Tempus AI, Inc. (Nasdaq: TEM) is a technology company advancing precision medicine through artificial intelligence and the world’s largest library of clinical and molecular data. Tempus delivers real-time, data-driven insights to physicians and researchers, enabling more accurate diagnoses, optimized therapies, and improved outcomes for patients. With a robust platform spanning oncology, cardiology, mental health, and infectious disease, Tempus is helping reshape how medicine is practiced and delivered—bringing the power of AI to the point of care.
By
